

Germline deletion of $\beta 2$ microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB/W F1 model of lupus

Singh *et al.*

RESEARCH ARTICLE

Open Access

Germline deletion of $\beta 2$ microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB/W F1 model of lupus

Ram Raj Singh^{1,2,3*}, Jun-Qi Yang¹, Peter J Kim¹ and Ramesh C Halder¹

Abstract

Introduction: $\beta 2$ -microglobulin ($\beta 2m$) is required for the surface expression of MHC class I and class I-like proteins such as CD1d, Qa1 and neonatal Fc receptor (FcRn), all of which may impact the development of autoimmunity. Since CD1d is known to bind and present phospholipid antigens to T cells, we asked if the deficiency of $\beta 2m$ or CD1d will impact the development of anti-phospholipid antibodies as compared to other aspects of lupus autoimmunity.

Methods: We introgressed the $\beta 2m$ -null genotype onto the NZB and NZW backgrounds for 12 to 14 generations to generate genetically lupus-susceptible (NZB/NZW)F1 (BWF1) mice that are $\beta 2m$ -deficient ($\beta 2m^{\circ}$). Circulating immunoglobulins (Ig), rheumatoid factor (RF), anti-DNA and anti-cardiolipin (anti-CL) antibodies, and renal disease were analyzed in these and CD1d-deficient (CD1d^o) BWF1 mice that we had previously generated.

Results: Whereas $\beta 2m^{\circ}$ BWF1 mice had reduced serum IgG, they had increased mortality, nephritis, serum IgG anti-DNA antibody and RF as compared to heterozygous and wild-type littermates. These effects were recapitulated in CD1d^o BWF1 mice, except that they also had increased serum IgG as compared to control littermates. Intriguingly, both $\beta 2m^{\circ}$ and CD1d^o mice had lower serum anti-CL antibody levels than in control littermates. Such CD1d dependence of anti-CL antibody production is not mediated by CD1d/glycolipid-reactive iNKT cells, as these cells reduced the production of RF and anti-DNA antibodies but had no effect on anti-CL antibodies.

Conclusions: We report a novel dichotomous role of $\beta 2m$ and CD1d, whereby these molecules differently regulate autoimmunity against phospholipid versus non-phospholipid autoantigens.

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by uncontrolled production of autoantibodies against a variety of antigens such as nucleic acids and phospholipids, hypergammaglobulinemia and multi-organ inflammation [1]. Diverse sets of T-cells - CD4⁺, TCR $\alpha\beta$ ⁺CD4⁻CD8⁻, or $\gamma\delta$ ⁺ T-cells - can promote autoantibody production [2-4]. The emergence

of such autoreactive T helper cells in lupus is accompanied by impaired regulatory mechanisms, which include CD8⁺, invariant natural killer T (NKT) and $\gamma\delta$ ⁺ T-cells [4-9]. Elucidating the role of antigen presenting molecules that present autoantigens to helper and regulatory T-cells would facilitate our understanding of the etiology and pathogenesis of lupus.

$\beta 2$ -microglobulin ($\beta 2m$) is required for the expression of cell surface molecules, including classical major histocompatibility complex (MHC) class I, CD1, Qa-1, and FcRn (neonatal Fc receptor), and for the development of CD8⁺, NKT, and CD3⁺CD4⁻CD8⁻ T-cell subsets [10,11], all of which may potentially impact the development of

* Correspondence: RRSingh@mednet.ucla.edu

¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles (UCLA), 1000 Veteran Avenue, Los Angeles, CA 90095-1670, USA

Full list of author information is available at the end of the article

humoral autoimmunity. In fact, several studies have used $\beta 2m^{\circ}$ mice to demonstrate a role of $\beta 2m$ -dependent events in the development of lupus. For example, $\beta 2m^{\circ}$ NZB mice have reduced anti-erythrocyte antibodies and hemolytic anemia [12], and $\beta 2m^{\circ}$ 129/J mice are resistant to an idiotype-induced experimental SLE [13]. $\beta 2m^{\circ}$ MRL-lpr/lpr mice also exhibit decreases in anti-DNA antibody production, hypergammaglobulinemia and lupus nephritis [14-16]. These protective effects of $\beta 2m$ deficiency have been linked with the absence of FcRn [15], which is known to inhibit immunoglobulin G (IgG) catabolism [17,18]. However, lupus dermatitis is aggravated in $\beta 2m^{\circ}$ MRL-lpr/lpr mice [16]. Mechanisms underlying such disparate effects of $\beta 2m$ -deficiency on autoimmune disease remain to be determined. Since $\beta 2m$ promotes the activation of CD8⁺ and NKT cells via its association with MHC class I and CD1d, respectively, $\beta 2m$ deficiency may aggravate aspects of autoimmunity that are normally controlled by such potentially regulatory T-cells [5-7].

CD1d can also bind phospholipid antigens [19,20] and activate T-cells [21,22]. We reasoned that the absence of such CD1d-restricted self-phospholipid-reactive T-cells might result in the decreased production of anti-phospholipid antibody in $\beta 2m^{\circ}$ and CD1d[°] mice. Here, we investigated the role of $\beta 2m$ on diverse aspects of lupus - survival, nephritis, hypergammaglobulinemia, rheumatoid factor (RF) and anti-DNA and anti-cardiolipin (anti-CL) autoantibodies - using a genetically susceptible animal model, namely NZB/NZW F1 (BWF1) mice that develop T-cell-dependent, autoantibody-mediated disease [23]. We show that $\beta 2m$ has distinct effects on diverse aspects of lupus autoimmunity.

Material and methods

Mice

The $\beta 2m^{\circ}$ 129xC57BL/6 mice were crossed onto the NZB and NZW backgrounds (all from Jackson Laboratory, Bar Harbor, ME, USA) for 12 to 14 generations. At each backcross the heterozygous ($\beta 2m^{+/-}$) mice were identified by PCR using the neo [24] and $\beta 2m$ primers (sense, 5'-TATCAGTCTCAGTGGGGGTG-3'; antisense, 5'-CTGAGCTCTGTTTTTCGTCTG-3'). The N12 $\beta 2m^{+/-}$ NZB mice were crossed with N12 or N14 $\beta 2m^{+/-}$ NZW mice to establish $\beta 2m^{+/+}$, $\beta 2m^{+/-}$, and $\beta 2m^{-/-}$ ($\beta 2m^{\circ}$) BWF1 mice. The CD1d^{-/-} (CD1d[°]) BWF1 mice were generated by crossing N10 CD1d^{+/-} NZB mice with N12 CD1d^{+/-} NZW mice [8]. The $\beta 2m^{\circ}$ and CD1d[°] phenotypes were further confirmed by demonstrating absence of CD1d by flow cytometry of peripheral blood lymphocytes using an anti-CD1d monoclonal antibody, 1B1 (PharMingen, San Diego, CA, USA). To confirm that mice at the final backcross are indeed congenic, they were screened using a battery of simple sequence repeat

markers (Jackson Laboratory), all of which discriminated congenic strains from the 129/B6 donors. V α 14^{Tg} BALB/c [25] and J α 18^{-/-} (J α 18[°]) BALB/c [26] mice were provided by Dr A Bendelac and Dr M Taniguchi, respectively. BALB/c SCID mice were purchased from Jackson Laboratory. All animal studies were performed according to the approved guidelines of UCLA Animal Research Committee.

Assessment of lupus disease

Survival, renal disease, and autoantibody and IgG levels were assessed. Proteinuria was measured on a 0 to 4+ scale using a colorimetric assay strip (Albustix, Bayer, Elkhart, IN, USA). Severe proteinuria was defined as ≥ 300 mg/dl on two consecutive examinations [6]. Kidney sections were stained with H & E, periodic acid-Schiff (PAS), and Masson's trichrome, and scored in a blind fashion [27,28]. In brief, the mean scores for individual pathological features were summed to obtain the four main scores, including glomerular activity score (GAS), tubulointerstitial activity score (TIAS), chronic lesion score (CLS), and vascular lesion score (VLS) (Additional file 1, Table S1). These scores were converted into indices by dividing them by the number of individual features examined to obtain those scores. The indices thus obtained were then averaged and summed to determine a composite kidney biopsy index.

Detection of autoantibodies

IgG anti-dsDNA antibody was measured by ELISA, as described [6], using serum samples diluted at 1:500 and the secondary antibody, alkaline phosphatase (AP)-conjugated goat-anti mouse IgG, at 1:1,000 dilution. Rheumatoid factor (RF, anti-IgG2a^a) was determined by ELISA, as described [29], using serum samples diluted at 1:250 and the secondary antibody, AP-conjugated goat-anti mouse kappa at 1:1,000 dilution. Anti-CL antibodies were detected as previously described [30]. In brief, ELISA plates were coated with CL Ag (5 μ g/ml, $\geq 97\%$ TCL, Sigma, St. Louis, MO, USA) in 200-proof ethyl alcohol (Daigger, Vernon Hills, IL, USA). Vehicle (200-proof ethyl alcohol only) served as a control. Plates were then dried under a hood for 30 minutes and blocked with 1% BSA for 1 h at room temperature. Samples (serum dilution 1:200 to 1:500) and standard were added into plates for 2 h at room temperature. After washing, plates were incubated with AP-conjugated goat-anti mouse IgG (1:1,000) (Southern Biotechnology, Birmingham, AL, USA), developed with p-nitrophenyl phosphate substrate (Sigma, MO, USA) and optical density (OD) was determined at 405 nm using Multiskan (Thermo Labsystems, Pittsburgh, PA, USA). Normal BALB/c serum was used as a negative control and pooled serum from old BWF1 or MRL-lpr mice was used as a reference positive

control. Total serum Ig and its isotypes were measured by a standard sandwich ELISA, using appropriate antibody pairs (Southern Biotechnology Associates, Birmingham, AL, USA), and serum samples diluted at 1:40,000 for total IgG and 1:20,000 for IgM and IgG isotypes. The secondary antibody, AP-conjugated goat-anti mouse IgG, IgM or IgG isotypes, was diluted at 1:1000.

Reconstitution of SCID mice

BALB/c SCID mice were injected intraperitoneally (i.p.) with 5 μ g LPS and 6 μ g α GalCer separately and transferred intravenously (i.v.) with purified B cells (1 to 3 $\times 10^7$) isolated from 10-month-old J α 18 $^\circ$ mice. These B-cell-reconstituted SCID mice were then transferred i.v. with enriched T-cells (3 to 6 $\times 10^6$) from donor 10-week-old V α 14 Tg or control J α 18 $^\circ$ mice. Four days after the transfer, spleen cells harvested from these mice were analyzed for T-cell receptor β (TCR β) and α GalCer/CD1d-dimer $^+$ cells to verify the reconstitution of SCID mice with iNKT cells, as described previously [31]. As expected, the recipients of J α 18 T cells had no iNKT cells; and recipients of V α 14 Tg T cells had iNKT cells in their spleen. Spleen cells from these mice were cultured in complete medium without any further stimulation for 6 days. Culture supernatants were tested for IgG anti-DNA and anti-CL antibodies.

Statistical analysis

Levels of antibodies and renal scores were compared using Student's *t*- or the Mann-Whitney *U*-test. Frequencies of antibodies and proteinuria were compared using two-sided Fisher's exact test. Survival was compared using a log-rank test.

Results

β 2m deficiency in BWF1 mice accelerates lupus nephritis and reduces survival

To investigate the role of β 2m in the pathogenesis of diverse manifestations of lupus, we generated N12 β 2m $^{+/-}$ NZB and N14 β 2m $^{+/-}$ NZW mice and intercrossed them to generate the final β 2m $^\circ$ BWF1 mice. As shown in Figure 1a, the cumulative survival was reduced in β 2m $^\circ$ mice as compared with β 2m $^{+/-}$ and β 2m $^{+/+}$ littermates ($n = 31$ to 66 animals per group). The reduction in survival in β 2m $^\circ$ mice was associated with a higher frequency and earlier onset of severe proteinuria than in controls (Figure 1b). To further document the extent of renal disease exacerbation in β 2m $^\circ$ mice, we scored stained renal sections (Figure 1c, d), which showed an increased composite kidney biopsy index as well as its components, glomerular activity and chronicity scores, in female (unpublished data) and in male mice that normally do not develop severe nephritis (Figure 1c). Vascular lesion scores, including thrombotic microangiopathy lesions, were not different among the three groups of mice

(unpublished data). Thus, inflammation and fibrotic disease, but not vascular disease, were accelerated in β 2m $^\circ$ mice.

β 2m deficiency in BWF1 mice reduces total serum IgG, but not IgM levels

Hypergammaglobulinemia is a feature of lupus. Thus, we expected to find increased IgG in β 2m $^\circ$ BWF1 mice that experienced severe disease (Figure 1). However, β 2m $^\circ$ BWF1 mice had reduced serum levels of total IgG and IgG2a as compared to β 2m $^{+/-}$ and β 2m $^{+/+}$ littermates (Figure 2a, b). Serum levels of total IgM (Figure 2c), however, were unaffected in β 2m $^\circ$ mice. Thus, β 2m $^\circ$ BWF1 mice experience disease exacerbation at an age when they have low levels of total IgG and the IgG isotype of most pathogenic autoantibodies, IgG2a [32].

β 2m $^\circ$ BWF1 mice have enhanced anti-DNA antibody and RF levels

Exacerbation of lupus, despite reduced IgG levels, in β 2m $^\circ$ mice raised a possibility that they develop disease via a mechanism that is not dependent on IgG autoantibodies. However, the frequency of positivity and serum levels of IgG anti-dsDNA antibody were higher in β 2m $^\circ$ mice than in control mice (Figure 3a, b). Male BWF1 mice, which normally do not develop autoantibodies in early life, had a marked increase in the prevalence of anti-dsDNA antibody (0% in β 2m $^{+/+}$ vs 31% in β 2m $^\circ$ mice at 4 months of age; $P = 0.01$; Fisher's exact test (data not shown)). Thus, anti-DNA B cells must be profoundly activated in β 2m $^\circ$ mice from early life.

The frequency of positive RF and its levels in β 2m $^\circ$ BWF1 mice showed a bimodal pattern, that is, its frequency and levels were lower than in β 2m sufficient mice in early life, but the frequency and levels increased in β 2m $^\circ$ mice to surpass the levels in the control littermates as the animals aged (Figure 3a, b). We surmise that the early decrease in RF in β 2m $^\circ$ mice may be related to the absence of FcRn, whereas the increased RF in later life may be due to increased activation of RF-producing B cells.

CD1d deficiency increases serum IgG and RF in BWF1 mice

The effects of β 2m on lupus described above could be mediated by a variety of cell surface molecules, such as FcRn, MHC class I, Qa1 and CD1d, which require β 2m for their optimal surface expression [10,11]. While reduced total IgG levels in the early life of β 2m $^\circ$ mice (Figure 2) can be explained by the absence of FcRn, the disease exacerbation in β 2m $^\circ$ BWF1 mice cannot be explained by FcRn-deficiency. Hence, we examined the effect of CD1d-deficiency on total IgG and autoantibody levels in the CD1d $^\circ$ BWF1 mice that we have generated [8]. We found






Figure 1 $\beta 2$ microglobulin ($\beta 2m$) deficiency reduces survival and accelerates lupus nephritis in BWF1 mice. We monitored 33 $\beta 2m^{-/-}$ ($\beta 2m^0$) (18 female and 15 male, open circles), 66 $\beta 2m^{+/-}$ (30 female and 36 male, triangles) and 31 $\beta 2m^{+/+}$ (18 female and 13 male, closed circles) littermates for the development of lupus. **(a)** Cumulative percent survival in $\beta 2m^0$ BWF1 mice was compared with control $\beta 2m^{+/-}$ and $\beta 2m^{+/+}$ littermate mice ($*P < 0.01$ to 0.05 , log rank test). **(b)** Cumulative percent mice with severe proteinuria (≥ 300 mg/dl protein on two consecutive occasions) was increased in $\beta 2m^0$ mice compared to control littermates ($*P = 0.02$ to 0.05 , Fisher's exact test). Differences were more pronounced ($P < 0.01$) when $\beta 2m^0$ mice were compared with all controls ($\beta 2m^{+/-}$ plus $\beta 2m^{+/+}$) mice. **(c)** Renal histological changes are expressed as the mean \pm standard error of the composite kidney biopsy index and its components, glomerular activity and chronicity scores. Results from a representative experiment are shown ($*P < 0.05$, $\beta 2m^0$ vs control groups; $n = 6$ to 8 male 10-month-old mice per group, Student's *t*-test). **(d)** Representative kidney sections from these mice show severe kidney lesions with fibrosis (note increased aniline blue staining) in the glomeruli (glomerulosclerosis, GS), periglomerular region (fibrous crescent, FC) and interstitium (IF), interstitial inflammation, and large segmental lesions (SL) in $\beta 2m^0$ mice, whereas the $\beta 2m^{+/+}$ mice showed relatively less advanced lesions with increased glomerular cellularity (GC) and typical immune deposits (ID, see pink-colored deposits), but minimal or no GS or IF. PAS, periodic acid Schiff.



that unlike $\beta 2m^0$ BWF1 mice that had lower serum levels of IgG than control littermates (Figure 2), CD1d⁰ BWF1 mice had significantly increased total serum IgG levels compared with CD1d⁺ littermates (Figure 4a). Serum RF, which is not normally detected in high titers in BWF1 mice, was also increased in the CD1d⁰ mice compared with CD1d⁺ littermates (Figure 4b). Serum IgG anti-dsDNA antibody levels and lupus nephritis were also elevated in CD1d⁰ BWF1 mice compared to controls (data not shown), as also reported previously [8]. Thus, the lack of a regulatory role of CD1d may explain, at least in part, the acceleration of lupus disease in $\beta 2m^0$ BWF1 mice.

Anti-CL antibody levels are reduced in $\beta 2m^0$ BWF1 mice

Preliminary analyses of autoantibodies using ELISA and western blot showed that a variety of antibodies against cellular and nuclear antigens were higher in $\beta 2m^0$ BWF1 mice than in control littermates (data not shown). Surprisingly, however, no $\beta 2m^0$ BWF1 mice had anti-CL antibodies above the cutoff level (mean + 4 (SD) OD in normal BALB/c mice). Subsequent analysis in a large cohort of mice showed that 6 to 10% of $\beta 2m^0$ BWF1 mice compared to 36 to 39% of control littermates were positive for IgG anti-CL antibodies at different ages ($P < 0.01$, Fisher's exact test). Levels of serum anti-phospholipid antibody were significantly lower in $\beta 2m^0$ BWF1 mice than in control littermates (Figure 5a, b). These data suggest a contribution of




$\beta 2m$ in the production of anti-CL antibodies in BWF1 mice.

CD1d plays a role in the production of anti-CL antibody

CD1d can bind phospholipid antigens [19,20] and activate T-cells [21,22]. We reasoned that the absence of such CD1d-restricted self-phospholipid-reactive T-cells might result in the decreased production of anti-phospholipid antibody in $\beta 2m^0$ and CD1d⁰ BWF1 mice. Indeed, serum IgG anti-phospholipid antibody levels were reduced in CD1d⁰ BWF1 mice compared with CD1d⁺ littermates (Figure 5c).

CD1d-restricted T cells comprise glycolipid-reactive iNKT cells that express the invariant TCR $V\alpha 14J\alpha 18$ and other NKT cells that do not express the invariant TCR. To determine the effect of iNKT cells on various autoantibodies, we cultured BWF1 spleen cells with glycolipid α GalCer. We found that while IgG anti-DNA antibody levels were reduced in the presence of α GalCer, IgG anti-CL antibody levels were unaffected (Figure 6a).



To further evaluate the differential effects of iNKT cells on anti-DNA versus anti-CL antibodies *in vivo*, we reconstituted BALB/c SCID mice with purified B cells



from iNKT cell-deficient J α 18° BALB/c mice (to avoid any contamination with iNKT cells or iNKT cell-exposed B cells). These mice were then implanted with T-cells from V α 14^{Tg} BALB/c mice that have >50% T-cells as iNKT cells or with T-cells from J α 18° BALB/c mice that have no iNKT cells. As shown in Figure 6b, spleen cells from SCID mice implanted with iNKT cells produced lower levels of IgG anti-DNA antibody levels than spleen cells from SCID mice implanted with J α 18° T-cells. However, anti-CL antibody levels were unaffected by the presence or absence of iNKT cells. These data suggest that while glycolipid-reactive iNKT cells suppress anti-DNA antibody production, they do not affect the development of anti-CL antibodies.

Discussion

Here, we show that BWF1 mice rendered deficient in β 2m exhibit markedly increased renal disease with reduced



survival, despite reduced serum IgG and IgG2a levels in early life. IgG anti-DNA antibody and RF are increased, but anti-phospholipid antibody levels are reduced in β 2m° mice. All, but one, of these effects of β 2m-deficiency may be explained, at least in part, by the absence of CD1d, with which β 2m non-covalently associates, as CD1d° BWF1 mice also have accelerated nephritis, increased IgG anti-DNA antibody and RF, but reduced anti-phospholipid antibody levels. However, unlike β 2m° mice, which have reduced serum IgG, CD1d° mice have increased serum IgG. Thus, β 2m-deficiency may affect lupus via at least three possible mechanisms: 1) the effects of FcRn on IgG catabolism; 2) the immunoregulatory role of CD1d, and 3) the ability of CD1d to bind phospholipids to induce anti-phospholipid autoimmunity.

IgG antibodies comprise the major isotype responsible for humoral immunity and the pathological effectors of lupus [32]. The FcRn protects IgG from catabolism by diverting it from a degradative fate in lysosomes [17,18]. The IgG molecules of FcRn-deficient mice have an abnormally short half-life [17,18]. Because a functional FcRn

molecule is dependent upon dimerization with $\beta 2m$, $\beta 2m^\circ$ mice also have reduced serum IgG [15,18]. Consistently, $\beta 2m^\circ$ BWF1 mice have reduced serum IgG in pre- and early disease stages (Figure 2), but not in 8-month-old female (Figure 2) and male and female mice with terminal disease (data not shown). This lack of decrease in total serum IgG in older $\beta 2m^\circ$ BWF1 mice could be due to a relative increase in IgG isotypes that bind weakly to FcRn and thus are less affected by the absence of FcRn. However, differences in the binding affinity of mouse FcRn for different mouse IgG isotypes are relatively small, with equilibrium dissociation constants (K_D) of 0.42, 0.5 and 0.75 for IgG2a, IgG2b and IgG1, respectively [33]. Mammalian FcRn is specific for IgG and does not bind IgA, IgM and IgE. Consistently, serum IgM levels were unaffected in $\beta 2m^\circ$ BWF1 mice. FcRn found on macrophages and dendritic cells can also facilitate the presentation of immune complexed antigens to T-cells [34,35]. Thus, the reduced antigen presentation and T-cell activation owing to FcRn-deficiency might contribute to the reduced IgG antibodies in $\beta 2m^\circ$ mice.

The above effects of FcRn, however, do not explain lupus exacerbation in $\beta 2m^\circ$ mice, which was severe enough to cause reduced survival (Figure 1a). Arguing against the role of FcRn in mediating the protective effect of $\beta 2m$ in lupus, the direct deficiency of FcRn did not affect survival in lupus-prone BXS.B.*Yaa* mice [36]. Importantly, the effect of FcRn cannot explain an increase in anti-DNA antibodies in $\beta 2m^\circ$ mice (Figure 3). Moreover, serum IgG increased as $\beta 2m^\circ$ mice aged (Figure 2), despite the lack of FcRn that protects IgG against degradation. Serum levels of IgG2a that binds most avidly to mouse FcRn were also increased as the $\beta 2m^\circ$ animals developed disease. Thus, a profound activation of autoreactive B-cells must occur in $\beta 2m^\circ$ mice to have increased levels of circulating autoantibodies.

We have previously reported that tolerance in anti-dsDNA B-cells can be broken by autoreactive T-cells in non-autoimmune mice [5]. Such breakdown of tolerance is curtailed, however, by the emergence of T-cells that can inhibit autoantibody production [5]. These inhibitory T-cells are mostly CD8⁺ T-cells that suppress autoantibody production via transforming growth factor β (TGF β) [5,28] or B-cell ablation [6]. The latter, cytotoxic, CD8⁺ T-cells recognize MHC class I-restricted peptides [6]. Expression of MHC class I molecule, Qa-1, by activated B-cells can also mediate CD8⁺ T-cell suppression of immune responses [37,38]. In fact, the genetic disruption of the inhibitory interaction between CD8⁺ T-cells and their target Qa-1⁺ T-cells results in the development of autoantibodies and nephritis [39]. Thus, both classical and non-classical MHC class I molecules might contribute to disease protection in $\beta 2m$ -intact BWF1 mice.

In resonance with the above, the deficiency of MHC class I molecules H-2K and H-2D, of Tap1, which is required for the loading of processed peptides onto H-2K/D, or of CD8 α , reduces survival in BXS.B.*Yaa* mice [36]. However, the acceleration in mortality in BXS.B.*Yaa* mice rendered deficient in H-2K/D, Tap1, or CD8 α was not as profound as that observed in $\beta 2m^\circ$ BXS.B.*Yaa* mice [36], suggesting that more than one mechanism likely accounts for the protective effect of $\beta 2m$ in lupus.

Not all studies favor a protective role of MHC class Ia/b-restricted CD8⁺ T-cells in lupus disease. For example, CD8-deficiency in NZB mice has been found to have no effect on anti-DNA antibody production [40]. The adoptive transfer of splenic CD8⁺ T-cells into $\beta 2m^\circ$ BWF1 mice also had no effect on disease in our preliminary study (data not shown). Thus, different mechanisms may account for the protective effect of $\beta 2m$ in different lupus-prone strains.

The disease-protective effects of $\beta 2m$ -dependent MHC class I proteins in BXS.B.*Yaa* mice could be attributed to the additive functions of CD8⁺ T-cells and IL-15 [36]. IL-15 also regulates the homeostasis and maturation of NKT-cells [41] that are restricted by CD1d, another $\beta 2m$ -associated molecule. Ample evidence suggests a regulatory role of CD1d-restricted T-cells in lupus and related diseases [8,24,31,42,43]. In fact, CD1d deficiency exacerbates nephritis and reduces survival in the hydrocarbon oil-induced and BWF1 models of lupus and dermatitis in MRL-*lpr* mice [8,24,42], although it has no effect on nephritis in MRL-*lpr* mice, or on survival in BXS.B.*Yaa* mice [16,36,42]. CD1d-deficiency increases the production of many autoantibodies including anti-DNA, anti-OJ and anti-ribosomal P antibodies [8,24], and RF (Figure 4). Recent evidence also indicates a direct regulation of autoreactive B-cells by CD1d-reactive NKT cells [31,44]. Thus, it is reasonable to suggest that the protective effects of $\beta 2m$ against humoral autoimmunity and nephritis may be mediated, at least in part, via the regulatory effect of CD1d-reactive NKT-cells.

CD1d-reactive T-cells comprise heterogeneous populations of cells [45,46]. In a previous study, adoptive transfer of CD1d-reactive single positive T-cells induced a lupus-like disease in nude mice, whereas CD1d-reactive TCR $\alpha\beta$ ⁺CD4⁻CD8⁻ T-cells prevented the induction of autoimmunity [47]. Thus, some CD1d-reactive T-cells might protect against autoimmunity, whereas others might enhance autoimmune disease. Such diverse CD1d-reactive T-cells are likely to recognize different antigens and exert different functions.

Some CD1d-restricted T-cells can recognize phospholipid antigens bound to CD1d [21,22]. Function of these phospholipid-reactive T-cells is not understood. We demonstrated that serum anti-phospholipid antibody

levels are reduced in $\beta 2m^{\circ}$ and $CD1d^{\circ}$ mice (Figure 5). These data for the first time raise a possibility that $CD1d$ presentation of self-phospholipids might induce anti-phospholipid autoantibodies, although further studies are needed to directly test this idea.

The reduction in anti-CL antibody levels in $CD1d^{\circ}$ mice was not due to a lack of anti-CL B-cell repertoire, as addition of lipopolysaccharide (LPS) to spleen cell cultures increased the levels of IgG anti-CL antibodies in these mice (Additional file 1, Figure S1). Thus, anti-CL B-cells exist in $CD1d^{\circ}$ mice, but they require $CD1d$ for their activation *in vivo*.

We have recently reported that $CD1d$ -restricted iNKT cells that respond to glycolipid $\alpha GalCer$ suppress the production of anti-DNA antibody and RF [31,48]. We asked whether such iNKT-cells promote anti-CL antibody production. In contrast to the effects of $\alpha GalCer$ on anti-DNA antibodies, anti-CL antibody levels were unaffected in BWF1 spleen cell cultures containing $\alpha GalCer$ (Figure 6a). Consistently, iNKT cells reduced IgG anti-DNA antibodies in SCID mice reconstituted with B-cells and iNKT-cells, but did not affect anti-CL antibody levels (Figure 6b). Thus, glycolipid-reactive type 1 iNKT-cells suppress the production of autoantibodies against non-phospholipid autoantigens, whereas non-iNKT cells, also called type 2 $CD1d$ -restricted T-cells, might promote anti-CL antibody production.

Although this study used N10-N14 backcrossed mice that are expected to carry $\leq 0.1\%$ genes from the 129/B6 $\beta 2m^{\circ}$ or $CD1d^{\circ}$ founders, there remains the possibility that our results reflect the alteration of linked gene(s) during the backcross of the mutated $\beta 2m$ or $CD1d$ 129 locus onto the lupus genetic backgrounds. Genotype analyses of our final backcrossed mice using simple sequence repeat markers, however, do not suggest a replacement with 129/B6 genes at any of the loci tested (data not shown). Moreover, differential regulation of different autoantibodies, increased anti-DNA and RF, and decreased anti-CL antibody, further suggests that the observed effects are not simply due to introgression of another gene that may have caused non-specific B-cell activation. Furthermore, similar data were obtained in more than one knockout strain, namely $\beta 2m^{\circ}$ and $CD1d^{\circ}$ BWF1, arguing against the possibility that other lupus-susceptibility genes are responsible for our observations.

Conclusions

Different MHC class I-related molecules associated with $\beta 2m$ play distinct roles in the development of different autoantibodies (Figure 7). A clear understanding of these roles may have implications for the development of novel therapies for the treatment of complex multi-system lupus disease. For example, inhibition or neutralization of




Figure 7 Distinct roles of different $\beta 2m$ -associated glycoproteins in the regulation of humoral autoimmunity. The findings in this report and previous studies suggest that $\beta 2m$ may affect lupus-like autoimmunity via at least six possible mechanisms: 1) neonatal Fc receptor (FcRn) effects on immunoglobulin G (IgG) catabolism [17,18] (Figure 2); 2) Qa-1-restricted $CD8^+$ regulatory or suppressor T-cells that can suppress autoimmunity [39]; 3) major histocompatibility complex (MHC) class I-restricted $CD8^+$ Ti cells (inhibitory T-cells) that suppress autoantibody production via production of transforming growth factor β [5,28]; 4) MHC class I-restricted $CD8^+$ cytotoxic T lymphocytes (CTL) that can ablate autoreactive B-cells [6]; 5) protective role of $CD1d$ -restricted glycolipid (GL)-reactive invariant natural killer T (iNKT)-cells in autoimmunity [8,24,31,42,44] (Figures 4 and 6a); and 6) the ability of $CD1d$ to bind phospholipid (PL) antigens to induce anti-phospholipid autoimmunity (Figure 5). RF, rheumatoid factor; APC, antigen presenting cell.

FcRn may increase IgG catabolism [17], thus reducing the levels of pathogenic IgG autoantibodies, and the activation of regulatory $CD8^+$ or iNKT-cells may protect against autoimmunity. Patients with SLE and related diseases have reduced numbers and/or functions of $CD1d$ -reactive T-cells [9,49-51], so the boosting of $CD1d$ -reactive T-cells should be explored as a therapeutic strategy in SLE. In fact, treatment with rituximab restores the numbers and functions of $CD1d$ -reactive T-cells to near-normal levels in patients with SLE [50]. There is a need for caution, however, as some $CD1d$ -restricted T-cells might activate anti-phospholipid B cells and might induce or worsen anti-phospholipid syndrome, which manifests with vascular thrombosis and loss of pregnancy [52]. Further studies are needed to dissect the roles of $CD1d$ -restricted glycolipid-reactive vs phospholipid-reactive T-cells in conferring the protective vs pathogenic roles in SLE.

Additional material

Additional file 1: Table S1: A table showing the renal biopsy scoring system. Scales for scores, indices and individual components. Figure S1: A figure showing that the reduction in anti-cardiolipin antibody levels in $CD1d^{\circ}$ mice is not due to a lack of anti-cardiolipin B cell repertoire in these mice. Anti-cardiolipin antibody levels in cultured supernatants of spleen cells stimulated with lipopolysaccharide (LPS) from wild-type (WT) and $CD1d^{\circ}$ mice.

Abbreviations

αGalCer: α-galactosylceramide; anti-CL: anti-cardiolipin; β2m^{-/-}: β2 microglobulin-deficient; BSA: bovine serum albumin; BWF1: NZB/NZW F1; CD1d^{-/-}: CD1d-deficient; CLS: chronic lesions score; DN: double negative; ELISA: enzyme-linked immunosorbent assay; FcRn: neonatal Fc receptor; GAS: glomerular activity score; H & E: hematoxylin and eosin; IgG: immunoglobulin G; IL: interleukin; i.p.: intraperitoneal; i.v.: intravenous; LPS: lipopolysaccharide; MHC: major histocompatibility complex; NKT: natural killer T; OD: optical density; PAS: periodic acid-Schiff; PCR: polymerase chain reaction; RF: rheumatoid factor; SLE: systemic lupus erythematosus; TCR β: T-cell receptor β; TGFβ: transforming growth factor β; TIAS: tubulointerstitial activity score; VLS: vascular lesion score.

Authors' contributions

RRS planned and supervised all aspects of this study. RRS, JY and RCH were involved in acquisition of data. All authors were involved in the analysis and interpretation of data. They all participated in the preparation of this manuscript and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

We sincerely thank Luc Van Kaer (Nashville, TN, USA) for helpful suggestions, Tam Bui, Jonathan Jacinto, Hongzhu Liu and Guosheng Wang of Autoimmunity and Tolerance Laboratory for technical help, A Bendelac (Chicago, IL, USA) and M Taniguchi (Yokohama, Japan) for Vα14^{T9} and Jα18^{-/-} mice, respectively, and Mark Shlomchik (New Haven, CT, USA) for providing reagents for the RF assay. This work was supported in part by grants from the National Institutes of Health (AI80778, AR56465, HD67413 and AR62593), the American Heart Association, and the Rheumatology Research Foundation.

Author details

¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles (UCLA), 1000 Veteran Avenue, Los Angeles, CA 90095-1670, USA. ²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 924 Westwood Blvd, Los Angeles, CA 90095, USA. ³Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Factor Building, Los Angeles, CA 90095, USA.

Received: 16 November 2012 Revised: 18 January 2013

Accepted: 19 March 2013 Published: 27 March 2013

References

1. Singh RR: SLE: translating lessons from model systems to human disease. *Trends Immunol* 2005, **26**:572-579.
2. Shivakumar S, Tsokos GC, Datta SK: T cell receptor α/β expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. *J Immunol* 1989, **143**:103-112.
3. Singh RR, Kumar V, Ebling FM, Southwood S, Sette A, Sercarz EE, Hahn BH: T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. *J Exp Med* 1995, **181**:2017-2027.
4. Peng SL, Madaio MP, Hayday AC, Craft J: Propagation and regulation of systemic autoimmunity by gammadelta T cells. *J Immunol* 1996, **157**:5689-5698.
5. Singh RR, Ebling FM, Albuquerque DA, Saxena V, Kumar V, Giannini EH, Marion TN, Finkelman FD, Hahn BH: Induction of autoantibody production is limited in nonautoimmune mice. *J Immunol* 2002, **169**:587-594.
6. Fan GC, Singh RR: Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. *J Exp Med* 2002, **196**:731-741.
7. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR: Repeated α-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. *J Immunol* 2003, **171**:4439-4446.
8. Yang JQ, Wen X, Liu H, Folyan G, Dong X, Zhou M, Van Kaer L, Singh RR: Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. *Arthritis Rheum* 2007, **56**:1219-1233.
9. Wither J, Cai YC, Lim S, McKenzie T, Roslin N, Claudio JO, Cooper GS, Hudson TJ, Paterson AD, Greenwood CM, Gladman D, Pope J, Pineau CA, Smith CD, Hanly JG, Peschken C, Boire G, CaNIOS Investigators, Fortin PR: Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity. *Arthritis Res Ther* 2008, **10**:R108.
10. Koller BH, Marrack P, Kappler JW, Smithies O: Normal development of mice deficient in β2M, MHC class I proteins, and CD8+ T cells. *Science* 1990, **248**:1227-1230.
11. Simister NE, Mostov KE: An Fc receptor structurally related to MHC class I antigens. *Nature* 1989, **337**:184-187.
12. Chen SY, Takeoka Y, Pike-Nobile L, Ansari AA, Boyd R, Gershwin ME: Autoantibody production and cytokine profiles of MHC class I (β2-microglobulin) gene deleted New Zealand black (NZB) mice. *Clin Immunol Immunopathol* 1997, **84**:318-327.
13. Mozes E, Kohn LD, Hakim F, Singer DS: Resistance of MHC class I-deficient mice to experimental systemic lupus erythematosus. *Science* 1993, **261**:91-93.
14. Christianson GJ, Blankenburg RL, Duffy TM, Panka D, Roths JB, Marshak-Rothstein A, Roopenian DC: β2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice. *J Immunol* 1996, **156**:4932-4939.
15. Christianson GJ, Brooks W, Vekasi S, Manolfi EA, Niles J, Roopenian SL, Roths JB, Rothlein R, Roopenian DC: β2-microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. *J Immunol* 1997, **159**:4781-4792.
16. Chan OT, Paliwal V, McNiff JM, Park SH, Bendelac A, Shlomchik MJ: Deficiency in β2-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) mice: an example of disease regulation at the organ level. *J Immunol* 2001, **167**:2985-2990.
17. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanesian L, Choi EY, Shaffer DJ, Eden PA, Anderson CL: The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. *J Immunol* 2003, **170**:3528-3533.
18. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES: Abnormally short serum half-lives of IgG in β2-microglobulin-deficient mice. *Eur J Immunol* 1996, **26**:690-696.
19. Joyce S, Woods AS, Yewdell JW, Bennink JR, De Silva AD, Boesteanu A, Balk SP, Cotter RJ, Brutkiewicz RR: Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. *Science* 1998, **279**:1541-1544.
20. Park JJ, Kang SJ, De Silva AD, Stanic AK, Casorati G, Hachey DL, Cresswell P, Joyce S: Lipid-protein interactions: biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved. *Proc Natl Acad Sci USA* 2004, **101**:1022-1026.
21. Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, Koezuka Y, Porcelli SA, Cardell S, Brenner MB, Behar SM: Murine CD1d-restricted T cell recognition of cellular lipids. *Immunity* 2000, **12**:211-221.
22. Rauch J, Gumperz J, Robinson C, Sköld M, Roy C, Young DC, Lafleur M, Moody DB, Brenner MB, Costello CE, Behar SM: Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. *J Biol Chem* 2003, **278**:47508-47515.
23. Hahn BH, Singh RR: Animal models of systemic lupus erythematosus. In *Dubois' Lupus Erythematosus*. 7 edition. Edited by: Wallace DJ, Hahn BH. Philadelphia: Lippincott, Williams and Wilkins; 2007:299-355.
24. Yang JQ, Singh AK, Wilson MT, Satoh M, Stanic AK, Park JJ, Hong S, Gadola SD, Mizutani A, Kakumanu SR, Reeves WH, Cerundolo V, Joyce S, Van Kaer L, Singh RR: Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. *J Immunol* 2003, **171**:2142-2153.
25. Bendelac A, Hunziker RD, Lantz O: Increased interleukin 4 and immunoglobulin E production in transgenic mice overexpressing NK1 T cells. *J Exp Med* 1996, **184**:1285-1293.
26. Cui J, Shin T, Kawano T, Sato H, Kondo E, Taura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M: Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. *Science* 1997, **278**:1623-1626.

27. De Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP, Singh RR: **An ACE inhibitor reduces Th2 cytokines and TGF- β 1 and TGF- β 2 isoforms in murine lupus nephritis.** *Kidney Int* 2004, **65**:846-859.
28. Saxena V, Lienesch DW, Zhou M, Bommireddy R, Azhar M, Doetschman T, Singh RR: **Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage.** *J Immunol* 2008, **180**:1903-1912.
29. Wang H, Shlomchik MJ: **Maternal Ig mediates neonatal tolerance in rheumatoid factor transgenic mice but tolerance breaks down in adult mice.** *J Immunol* 1998, **160**:2263-2271.
30. Ede K, Hwang KK, Wu CC, Wu M, Yang YH, Lin WS, Chien D, Chen PC, Tsao BP, McCurdy DK, Chen PP: **Plasmin immunization preferentially induces potentially prothrombotic IgG anticardiolipin antibodies in MRL/MpJ mice.** *Arthritis Rheum* 2009, **60**:3108-3117.
31. Yang JQ, Wen X, Kim PJ, Singh RR: **Invariant NKT cells inhibit autoreactive B cells in a contact- and CD1d-dependent manner.** *J Immunol* 2011, **186**:1512-1520.
32. Ohnishi K, Ebling FM, Mitchell B, Singh RR, Hahn BH, Tsao BP: **Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics.** *Int Immunol* 1994, **6**:817-830.
33. Zhou J, Johnson JE, Ghetie V, Ober RJ, Ward ES: **Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G.** *J Mol Biol* 2003, **332**:901-913.
34. Liu X, Lu L, Yang Z, Palaniyandi S, Zeng R, Gao LY, Mosser DM, Roopenian DC, Zhu X: **The neonatal FcR-mediated presentation of immune-complexed antigen is associated with endosomal and phagosomal pH and antigen stability in macrophages and dendritic cells.** *J Immunol* 2011, **186**:4674-4686.
35. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS: **Dependence of antibody-mediated presentation of antigen on FcRn.** *Proc Natl Acad Sci USA* 2008, **105**:9337-9342.
36. McPhee CG, Sproule TJ, Shin DM, Bubier JA, Schott WH, Steinbuck MP, Avenesyan L, Morse HC, Roopenian DC: **MHC class I family proteins retard systemic lupus erythematosus autoimmunity and B cell lymphomagenesis.** *J Immunol* 2011, **187**:4695-4704.
37. Noble A, Zhao ZS, Cantor H: **Suppression of immune responses by CD8 cells. II. Qa-1 on activated B cells stimulates CD8 cell suppression of T helper 2 responses.** *J Immunol* 1998, **160**:566-571.
38. Jiang H, Chess L: **The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1.** *Annu Rev Immunol* 2000, **18**:185-216.
39. Kim HJ, Verbinen B, Tang X, Lu L, Cantor H: **Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance.** *Nature* 2010, **467**:328-332.
40. Chen SY, Takeoka Y, Ansari AA, Boyd R, Klinman DM, Gershwin ME: **The natural history of disease expression in CD4 and CD8 gene-deleted New Zealand black (NZB) mice.** *J Immunol* 1996, **157**:2676-2684.
41. Gordy LE, Bezbradica JS, Flyak AI, Spencer CT, Dunkle A, Sun J, Stanic AK, Boothby MR, He YW, Zhao Z, Van Kaer L, Joyce S: **IL-15 regulates homeostasis and terminal maturation of NKT cells.** *J Immunol* 2011, **187**:6335-6345.
42. Yang JQ, Chun T, Liu H, Hong S, Bui H, Van Kaer L, Wang CR, Singh RR: **CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice.** *Eur J Immunol* 2004, **34**:1723-1732.
43. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H: **The regulatory role of Va14 NKT cells in innate and acquired immune response.** *Annu Rev Immunol* 2003, **21**:483-513.
44. Wermeling F, Lind SM, Jordo ED, Cardell SL, Karlsson MC: **Invariant NKT cells limit activation of autoreactive CD1d-positive B cells.** *J Exp Med* 2010, **207**:943-952.
45. Behar SM, Cardell S: **Diverse CD1d-restricted T cells: diverse phenotypes, and diverse functions.** *Semin Immunol* 2000, **12**:551-560.
46. Gumperz JE, Miyake S, Yamamura T, Brenner MB: **Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining.** *J Exp Med* 2002, **195**:625-636.
47. Zeng D, Dick M, Cheng L, Amano M, Dejbakhsh-Jones S, Huie P, Sibley R, Strober S: **Subsets of transgenic T cells that recognize CD1 induce or prevent murine lupus: role of cytokines.** *J Exp Med* 1998, **187**:525-536.
48. Yang JQ, Kim PJ, Singh RR: **Brief treatment with iNKT cell ligand alpha-galactosylceramide confers a long-term protection against lupus.** *J Clin Immunol* 2012, **32**:106-113.
49. Oishi Y, Sumida T, Sakamoto A, Kita Y, Kurasawa K, Nawata Y, Takabayashi K, Takahashi H, Yoshida S, Taniguchi M, Saito Y, Iwamoto I: **Selective reduction and recovery of invariant Va24JaQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus.** *J Rheumatol* 2001, **28**:275-283.
50. Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C: **Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells.** *Immunity* 2012, **36**:477-490.
51. Cho YN, Kee SJ, Lee SJ, Seo SR, Kim TJ, Lee SS, Kim MS, Lee WW, Yoo DH, Kim N, Park YW: **Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity.** *Rheumatology (Oxford)* 2011, **50**:1054-1063.
52. Padmakumar K, Singh RR, Rai R, Malaviya AN, Saraya AK: **Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations.** *Ann Rheum Dis* 1990, **49**:986-989.

doi:10.1186/ar4206

Cite this article as: Singh et al.: Germline deletion of β 2 microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB/W F1 model of lupus. *Arthritis Research & Therapy* 2013 **15**:R47.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

